CD8A and neoplasm: NT-I7, a longer-acting IL-7 Fc, was tested for its ability to prevent systemic lymphopenia and improve survival in a GBM mouse model, and it was demonstrated that in a mouse model of glioma in situ, NT-I7 increased central and effector memory CD8+ T cells in both lymphoid organs and tumours [81].